Top

Published in:

01-04-2013 | Review

Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

Authors: Justine Bacchetta, Isidro B. Salusky, Martin Hewison

Published in: Pediatric Nephrology | Issue 4/2013

Abstract

Fibroblast growth factor 23 (FGF23) is an “endocrine” FGF acting in the kidney as a phosphaturic hormone and a suppressor of active vitamin D, through an inhibition of the 1α hydroxylase and a stimulation of the 24 hydroxylase. Beyond its well-known effects on the bone/kidney/parathyroid axis and its deregulation during chronic kidney disease (CKD), recent evidence has revealed its direct systemic effects on cardiovascular health. In the meantime, studies have highlighted the health implications for vitamin D inside and outside CKD that also extend beyond its classical actions on mineral homeostasis and bone metabolism: vitamin D has indeed been shown to exert pluripotent non-classical effects as a modulator of immune function in monocytes, mainly through the stimulation of the antimicrobial cathelicidin. The aim of this review is to provide new insights on the interplay between FGF23 and vitamin D in innate immunity in the context of CKD.

Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637–1647PubMedCrossRef

Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509–1518PubMedCrossRef

Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N (2007) Mineralized tissue cells are a principal source of FGF23. Bone 40:1565–1573PubMedCrossRef

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435PubMedCrossRef

Razzaque MS (2009) Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant 24:4–7PubMedCrossRef

Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125–131PubMedCrossRef

Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003–4008PubMed

Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H (2010) Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95:578–585PubMedCrossRef

Lafage-Proust MH (2010) Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int 77:390–392PubMedCrossRef

10.

Juppner H, Wolf M, Salusky IB (2010) FGF23: more than a regulator of renal phosphate handling? J Bone Miner Res 25:2091–2097PubMedCrossRef

11.

Prie D, Urena Torres P, Friedlander G (2009) Latest findings in phosphate homeostasis. Kidney Int 75:882–889PubMedCrossRef

12.

Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439PubMedCrossRef

13.

Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, Lind L, Larsson TE (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24:3125–3131PubMedCrossRef

14.

Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205:385–390PubMedCrossRef

15.

Fukagawa M, Nii-Kono T, Kazama JJ (2005) Role of fibroblast growth factor 23 in health and in chronic kidney disease. Curr Opin Nephrol Hypertens 14:325–329PubMedCrossRef

16.

Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedCrossRef

17.

Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171–1178PubMedCrossRef

18.

Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED (2011) Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 26:945–951PubMedCrossRef

19.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408PubMedCrossRef

20.

Chonchol M, Kendrick J, Targher G (2011) Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Ann Med 43:273–282PubMedCrossRef

21.

Adams JS, Hewison M (2010) Update in vitamin D. J Clin Endocrinol Metab 95:471–478PubMedCrossRef

22.

Adams JS, Hewison M (2008) Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 4:80–90PubMedCrossRef

23.

Bacchetta J, Ranchin B, Dubourg L, Cochat P (2010) Vitamin D revisited: a cornerstone of health? Arch Pediatr 17:1687–1695PubMedCrossRef

24.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770–1773PubMedCrossRef

25.

Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, Borregaard N, Modlin RL, Hewison M (2009) Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J Immunol 182:4289–4295PubMedCrossRef

26.

Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK (2008) Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23:1831–1836PubMedCrossRef

27.

Belostotsky V, Mughal MZ, Berry JL, Webb NJ (2008) Vitamin D deficiency in children with renal disease. Arch Dis Child 93:959–962PubMedCrossRef

28.

Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P (2010) The Influence of Glomerular Filtration Rate and Age on Fibroblast Growth Factor 23 Serum Levels in Pediatric Chronic Kidney Disease. J Clin Endocrinol Metab 95:1741–1748PubMedCrossRef

29.

Shroff R, Wan M, Gullet A, Ledermann S, Shute R, Knott C, Wells D, Aitkenhead H, Manickavasagar B, van’t Hoff W, Rees L (2012) Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol doi:10.2215/CJN.04760511

30.

Parasuraman R, Samarapungavan D, Venkat KK (2010) Updated principles and clinical caveats in the management of infection in renal transplant recipients. Transplant Rev (Orlando) 24:43–51CrossRef

31.

Cohen G, Haag-Weber M, Horl WH (1997) Immune dysfunction in uremia. Kidney Int Suppl 62:S79–S82PubMed

32.

Dalrymple LS, Go AS (2008) Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 3:1487–1493PubMedCrossRef

33.

Viasus D, Garcia-Vidal C, Cruzado JM, Adamuz J, Verdaguer R, Manresa F, Dorca J, Gudiol F, Carratala J (2011) Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant 26:2899–2906PubMedCrossRef

34.

Sarnak MJ, Jaber BL (2001) Pulmonary infectious mortality among patients with end-stage renal disease. Chest 120:1883–1887PubMedCrossRef

35.

Sarnak MJ, Jaber BL (2000) Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 58:1758–1764PubMedCrossRef

36.

Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, Coyne DW, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ (2003) Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. JASN 14:1863–1870PubMedCrossRef

37.

Harambat J, van Stralen KJ, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363–373PubMedCrossRef

38.

Mong Hiep TT, Ismaili K, Collart F, Van Damme-Lombaerts R, Godefroid N, Ghuysen MS, Van Hoeck K, Raes A, Janssen F, Robert A (2010) Clinical characteristics and outcomes of children with stage 3–5 chronic kidney disease. Pediatr Nephrol 25:935–940PubMedCrossRef

39.

Sardenberg C, Suassuna P, Andreoli MC, Watanabe R, Dalboni MA, Manfredi SR, dos Santos OP, Kallas EG, Draibe SA, Cendoroglo M (2006) Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function. Nephrol Dial Transplant 21:160–165PubMedCrossRef

40.

Lim WH, Kireta S, Leedham E, Russ GR, Coates PT (2007) Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 72:1138–1148PubMedCrossRef

41.

Vogtlander NP, Brown A, Valentijn RM, Rimmelzwaan GF, Osterhaus AD (2004) Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients. Vaccine 22:2199–2201PubMedCrossRef

42.

Buti M, Viladomiu L, Jardi R, Olmos A, Rodriguez JA, Bartolome J, Esteban R, Guardia J (1992) Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 12:144–147PubMedCrossRef

43.

Krutzik SR, Hewison M, Liu PT, Robles JA, Stenger S, Adams JS, Modlin RL (2008) IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol 181:7115–7120PubMed

44.

Baeke F, van Etten E, Gysemans C, Overbergh L, Mathieu C (2008) Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Aspects Med 29:376–387PubMedCrossRef

45.

Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, Rutgeerts O, Saint-Arnaud R, Bouillon R, Mathieu C (2000) Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 120:139–146PubMedCrossRef

46.

Vidal M, Ramana CV, Dusso AS (2002) Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol 22:2777–2787PubMedCrossRef

47.

Gombart AF, Borregaard N, Koeffler HP (2005) Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 19:1067–1077PubMedCrossRef

48.

Chun RF, Adams JS, Hewison M (2008) Back to the future: a new look at ‘old’ vitamin D. J Endocrinol 198:261–269PubMedCrossRef

49.

Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA Jr, Koeffler HP, Thadhani R (2009) Low Plasma Level of Cathelicidin Antimicrobial Peptide (hCAP18) Predicts Increased Infectious Disease Mortality in Patients Undergoing Hemodialysis. Clin Infect Dis 48:418–424PubMedCrossRef

50.

Andrukhova O, Zeitz U, Goetz R, Mohammadi M, Lanske B, Erben RG (2012) FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 51:621–628PubMedCrossRef

51.

Edfeldt K, Liu PT, Chun R, Fabri M, Schenk M, Wheelwright M, Keegan C, Krutzik SR, Adams JS, Hewison M, Modlin RL (2010) T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci U S A 107:22593–22598PubMedCrossRef

52.

Bacchetta J, Sea J, Chun R, Lisse T, Wesseling-Perry K, Gales B, Adams J, Salusky IB, Hewison M (2012) FGF23 inhibits extra-renal synthesis of 1-25-dihydroxyvitamin D in human monocytes. J Bone Miner Res doi: 10.1002/jbmr.1740

Title: Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?
Authors: Justine Bacchetta
Isidro B. Salusky
Martin Hewison
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 4/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-012-2336-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Aldosterone contributes to elevated left ventricular mass in black boys

Vitamin D and inflammation

Cystatin C in children on chronic hemodialysis

Inflammation and linear bone growth: the inhibitory role of SOCS2 on GH/IGF-1 signaling

FGF23 production by osteocytes

Ocular involvement in a child with medullary nephrocalcinosis: Questions